We are live on ! Find out more
CSCI

COSCIENS Biopharma Inc. Common Stock

Delisted

CSCI was delisted on the 3rd of September, 2025.

26 hedge funds and large institutions have $4.22M invested in COSCIENS Biopharma Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

236% more call options, than puts

Call options by funds: $1.17M | Put options by funds: $347K

0% more funds holding

Funds holding: 2626 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0.05% less ownership

Funds ownership: 0.14%0.09% (-0.05%)

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

60% less capital invested

Capital invested by funds: $10.6M → $4.22M (-$6.38M)

Holders
26
Holders Change
Holders Change %
0%
% of All Funds
0.56%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
6
Reduced
9
Closed
6
Calls
$1.17M
Puts
$347K
Net Calls
+$819K
Net Calls Change
+$557K

CSCI Hedge Fund Activity: Q2 2019 in Review

26 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2019, worth a combined $4.22M — down 60% from $10.6M a quarter earlier.

Fund positioning in CSCI was balanced in Q2 2019: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $161K. The largest seller was J. Goldman & Co, cutting an estimated $1.25M.

  • 26 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $4.22M of COSCIENS Biopharma Inc. Common Stock stock for Q2 2019, down 60% quarter-over-quarter.
  • 6 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2019 and 6 closed out, a net change of 0 holders.
  • The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2019 was BlackRock, an estimated $161K added.
  • The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2019 was J. Goldman & Co, an estimated $1.25M sold.

Based on aggregated 13F filings for Q2 2019.